Index Investing News
Friday, May 30, 2025
No Result
View All Result
  • Login
  • Home
  • World
  • Investing
  • Financial
  • Economy
  • Markets
  • Stocks
  • Crypto
  • Property
  • Sport
  • Entertainment
  • Opinion
  • Home
  • World
  • Investing
  • Financial
  • Economy
  • Markets
  • Stocks
  • Crypto
  • Property
  • Sport
  • Entertainment
  • Opinion
No Result
View All Result
Index Investing News
No Result
View All Result

Co-Diagnostics: Awaiting Evidence Of Pivot From COVID-19

by Index Investing News
November 22, 2022
in Stocks
Reading Time: 5 mins read
A A
0
Home Stocks
Share on FacebookShare on Twitter


Images By Tang Ming Tung

Investment Summary

Since our last coverage of Co-Diagnostics, Inc. (NASDAQ:CODX), we’ve retained our neutral view on the company. Last time, our price target of $3.24 was premised by the following:

  1. Diminishing Covid-19 turnover, coupled with concentration risk in the company’s diagnostics segment to SARS-CoV-2.
  2. Surging inventory levels on the balance sheet coupled with the lack of inventory turnover, assay revenue.
  3. Innovations are in the pipeline, however, still some time to go before we see these on-market.
  4. An 81.6% YoY decrease in revenue for Q2 FY22 with contracting demand for its Logix Smart Covid-19 test the main driver.

As a reminder, CODX is developing its polymerase chain reaction (“PCR”) technology. It develops a suite of diagnostic tests, ranging from Covid-19 hepatitis B, tuberculosis, HPV, malaria, and many more. It benefitted from Covid-19 in terms of revenue and core EBITDA growth.

The stock trades in-line with our price target and following its Q3 FY22 numbers we observe the same central downside themes as noted above. Shares now trade at 7.3x trailing earnings – well below sector averages – and management didn’t provide forward guidance on the earnings call. Although, we don’t think this is cheap. Further, we forecast declining EPS growth into FY23, confirming our thesis. Net-net, we retain our buy call at a $3.24 price target.

Key upside risks to the thesis include:

  • CODX surprises to the upside in its next earnings with strong Covid-19 revenue.
  • With that, a large uptick in Covid-19 cases resulting in large demand for testing.
  • Volatility within trading of small-cap stocks, where market pricing can become disconnected from fundamentals. This can result in large price movements.
  • Investors should understand these risks for CODX before proceeding, to make the most informed decisions possible.

Exhibit 1. CODX 12-month weekly price action

44

Data: Updata

CODX Q3 numbers: structural headwinds remain

The company reported its Q3 earnings 2 weeks ago. Covid-19 demand continues to weaken with testing volumes tightening globally.

Management report it is focused on pivoting the diagnostics menu away from Covid-19, however, for the time being, this is the main driver of top-line growth for the company looking ahead in our opinion.

Per CEO, Dwight Egan’s comments on the call:

“COVID wave won’t be just one wave, but a series of waves, each fuelled by different variant that form a table meso or a table-like plateau. Aside from our belief that COVID-19 will be with us for a long time, we continue to rely on the advice of experts such as Dr. Fauci, who according to Fortune, has been warning for months that a new, more immune-evasive variant will emerge over the winter. Fauci also stresses that the pandemic is far from over. The number of deaths from COVID, which still averages around 2,600 a week, remains far too high…

…This is why our focus has been and continues to be on defining and focusing on the total addressable market for our new Co-Dx PCR Home platform…

…Among the opportunities that we have already identified have been collaborations with international NGOs and nonprofits.

The interest of these groups in the new platform extends beyond COVID to other endemic diseases such as tuberculosis, which killed 1.6 million people in 2021 alone according to the World Health Organization.”

Switching to the numbers, the company saw another 83.1% YoY downturn in revenue growth to $5.1mm. This compares to $30.1mm a year ago. Covid-19 testing volume was the key driver, as mentioned. Similarly, gross profit was down c.84% to $4.3mm on a margin of ~85%.

We note the following key data points from CODX’s performance in Q3:

  1. Cash conversion from receivables is a plus and serves to potentially grow revenue in periods to come. In the 9 months to September 30, 2022, it drew accounts receivable down from $20.84mm to $7.96mm. It brought in $10.6mm in net CFFO across the same period. We note that $1.1mm, or 10.4%, of this occurred in Q3 FY22. Hence, the majority of cash-conversion [89.6%] occurred pre-third quarter.
  2. We note the company has now completed $13mm of the $30mm authorized for its share repurchase program. This is 3.4mm shares – or 10% – of shares outstanding [from the count at the time of its annual meeting]. We believe there’s far better use for this capital and could be used to increase net operating after tax (“NOPAT”).
  3. With Covid-19 revenue diminishing, and despite a slight uptick in cases in the back half of 2022, the company’s now recognized sequential operating losses in Q2/Q3 FY22. It booked a $6.5mm operating loss on core EBITDA of negative $6.2mm this period, despite its R&D investment decreasing to $5mm from $5.89mm from the year prior.

We agree with the company’s data that Covid-19 will be around for a long time. Question is, what that means for a company like CODX, versus large, established players with commercial leverage. It continues to push Covid-19 revenues, in an industry that increasingly looks on consolidating.

With its latest set of operating losses, future value creation is called into question. It needs to generate a return on its investments greater than the cost of capital in order to unlock corporate value.

With heavy reliance on Covid-19, that’s a concentration risk and structural headwind that we aren’t keen on gaining exposure too. Alas, with the market outlook on Covid-19 murky, this regrettably confirms our neutral position.

Valuation and conclusion

Turning to our last CODX publication, we priced the stock at 18x our FY23 EPS estimates, or $3.24. This was well supported by technical data, similar to that seen in the point and figure chart of Exhibit 2.

The lack of earnings upside, coupled with poor return on invested capital in the past 2 quarters renders it difficult to value CODX at a premium. You can see our EPS assumptions for CODX into FY23 below. The entire set of growth assumptions can be seen in Appendix 1.

At its current run-rate, we see it printing a loss of $0.65 per share next year. Unfortunately, this doesn’t align with the kind of equity premia we are chasing in FY22. As such, we retain our hold rating and price target of $3.24.

Exhibit 2. Forward EPS growth estimates. Key factors to note:

  • Despite management’s optimism about Covid-19 demand-pull, we don’t see this matching up with bottom-line growth.
  • This presents a risk to our equity budget as we are seeking tacking positions that offer EPS upside.
  • Our assumptions are built by the fact CODX has seen sequential >80% YoY revenue, gross profit declines in Q2 and Q3 FY22.

444

Data: HB Insights Estimates

Exhibit 3.Price visibility around $3.24 well supported

44

Data: Updata4

Net-net, we retain our hold rating at $3.24 for CODX following its latest set of numbers. We look forward to providing further coverage in the periods to come.

Appendix 1. CODX Consolidated Forward Estimates, FY22-FY23

Note: Assumptions driven by substantial YoY revenue declines in Q2 and Q3 FY22.

44

Data: HB Insights Estimates



Source link

Tags: AwaitingCoDiagnosticsCOVID19EvidencePivot
ShareTweetShareShare
Previous Post

Bank of America Waits On Sideline Till Ripple Vs SEC Settles

Next Post

Children buried alive in collapsed schools after Indonesia earthquake and horror landslides as death toll hits 268

Related Posts

Is the Subscription Definitely worth the Price?

Is the Subscription Definitely worth the Price?

by Index Investing News
May 30, 2025
0

For critical buyers, real-time info and knowledgeable insights could make the distinction between commerce and a fantastic one. CNBC Professional...

Salesforce, Inc. (CRM) Jefferies Public Know-how Convention (Transcript)

Salesforce, Inc. (CRM) Jefferies Public Know-how Convention (Transcript)

by Index Investing News
May 29, 2025
0

Salesforce, Inc. (NYSE:CRM) Jefferies Public Know-how Convention Could 29, 2025 3:00 PM ET Firm Contributors Invoice Patterson - EVP, Company...

Nvidia Inventory’s Put up-Earnings Bump May Not Final (NVDA)

Nvidia Inventory’s Put up-Earnings Bump May Not Final (NVDA)

by Index Investing News
May 29, 2025
0

This text was written byObservePresently main analysis at Leverage Shares, I've longstanding skilled expertise with monetary markets. All views are...

GGN.PR.B: An Engaging Charges Play From This CEF (NYSE:GGN.PR.B)

GGN.PR.B: An Engaging Charges Play From This CEF (NYSE:GGN.PR.B)

by Index Investing News
May 29, 2025
0

This text was written byObserveWith an funding banking money and derivatives buying and selling background, Binary Tree Analytics ('BTA') goals...

Previous Republic Stays An Underappreciated Dividend Gem (ORI)

Previous Republic Stays An Underappreciated Dividend Gem (ORI)

by Index Investing News
May 29, 2025
0

This text was written byObserveThe Low-Finances Dividend Investor is your prototypical Era X-er: an over-educated, under-funded middle-aged man in search...

Next Post
Children buried alive in collapsed schools after Indonesia earthquake and horror landslides as death toll hits 268

Children buried alive in collapsed schools after Indonesia earthquake and horror landslides as death toll hits 268

FT Tech for Growth Forum

FT Tech for Growth Forum

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

RECOMMENDED

Can Tech Recover? With Alex King From Cestrian Capital Research

Can Tech Recover? With Alex King From Cestrian Capital Research

December 17, 2022
‘Guardians of the Galaxy Volume 3’ Says Animals Rule and Humanoids Drool

‘Guardians of the Galaxy Volume 3’ Says Animals Rule and Humanoids Drool

April 30, 2023
5 Ideas That Define the 2020s Financial Market

5 Ideas That Define the 2020s Financial Market

May 20, 2023
How Eviction Diversion Applications Are Driving Charges (and Prices) Down

How Eviction Diversion Applications Are Driving Charges (and Prices) Down

September 12, 2024
Can You Nonetheless Discover On-Market, Money Flowing Leases in 2024?

Can You Nonetheless Discover On-Market, Money Flowing Leases in 2024?

November 6, 2024
Bob Iger Explores the Sale of More Films and TV Series to Rivals

Bob Iger Explores the Sale of More Films and TV Series to Rivals

February 5, 2023
Bloomsbury sales hit record as readers opt for affordable entertainment

Bloomsbury sales hit record as readers opt for affordable entertainment

May 31, 2023
The Conservative Merciless Children – Econlib

The Conservative Merciless Children – Econlib

March 14, 2025
Index Investing News

Get the latest news and follow the coverage of Investing, World News, Stocks, Market Analysis, Business & Financial News, and more from the top trusted sources.

  • 1717575246.7
  • Browse the latest news about investing and more
  • Contact us
  • Cookie Privacy Policy
  • Disclaimer
  • DMCA
  • Privacy Policy
  • Terms and Conditions
  • xtw18387b488

Copyright © 2022 - Index Investing News.
Index Investing News is not responsible for the content of external sites.

No Result
View All Result
  • Home
  • World
  • Investing
  • Financial
  • Economy
  • Markets
  • Stocks
  • Crypto
  • Property
  • Sport
  • Entertainment
  • Opinion

Copyright © 2022 - Index Investing News.
Index Investing News is not responsible for the content of external sites.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In